Detalhe da pesquisa
1.
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
J Am Acad Dermatol
; 89(3): 486-495, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37182701
2.
Efficacy and safety of fumaric acid esters in combination with phototherapy in patients with moderate-to-severe plaque psoriasis (FAST).
J Dtsch Dermatol Ges
; 15(2): 180-186, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-28214304
3.
Wirksamkeit und Sicherheit von Fumarsäureestern in Kombination mit Phototherapie bei Patienten mit moderater bis schwerer Plaque-Psoriasis (FAST).
J Dtsch Dermatol Ges
; 15(2): 180-188, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-28214309
4.
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.
Dermatol Ther (Heidelb)
; 12(8): 1777-1792, 2022 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-35798920
5.
Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO.
Dermatol Ther (Heidelb)
; 12(1): 203-221, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34913153